Managing diabetes effectively often depends on having the right monitoring tools, and for millions of Americans enrolled in Medicare, understanding how continuous glucose monitors fit into their coverage can make a meaningful difference in day-to-day health management.
What Medicare Covers When It Comes to Glucose Monitors
Medicare provides coverage for continuous glucose monitors (CGMs) through Part B, classifying them as durable medical equipment (DME). This means that once a beneficiary meets the Part B deductible, they are responsible for paying 20% of the Medicare-approved amount for the device and related supplies (source). For many people managing diabetes, this cost-sharing structure can represent a significant reduction compared to paying entirely out of pocket.
It is worth noting that not all CGM devices automatically qualify under this benefit. Devices that display results only on a smartphone — without a stand-alone receiver or integration into an insulin pump — do not meet Medicare’s definition of durable medical equipment and will be denied as non-covered (source). Beneficiaries should confirm that any device they are considering meets Medicare’s equipment definition before pursuing coverage.
Who Qualifies for Medicare CGM Coverage
Medicare’s eligibility rules for CGMs have evolved considerably in recent years. As of April 16, 2023, individuals using any type or amount of insulin to manage their diabetes became eligible for CGM coverage — removing a previous restriction that required a specific daily insulin dosage (source). This change opened the door for a broader population of insulin users who previously fell outside the coverage threshold.
Perhaps even more significant is the expansion of coverage to certain non-insulin users. Medicare now extends CGM access to people with diabetes who do not take insulin, provided they have a documented history of problematic hypoglycemia — such as repeated moderate hypoglycemic episodes or a single severe event that required assistance from another person (source). This represents a meaningful policy shift that acknowledges the monitoring needs of a wider range of patients.
The type of diabetes a beneficiary has — whether type 1 or type 2 — does not determine eligibility on its own. What matters is having a confirmed diabetes diagnosis and satisfying the applicable criteria related to insulin use or hypoglycemia history (source).
Provider and Documentation Requirements
Medicare places specific requirements on both the prescribing provider and the beneficiary to ensure CGM coverage is appropriately granted. Before a CGM order is placed, the treating practitioner must conduct an in-person or Medicare-approved telehealth visit with the beneficiary within the six months prior to ordering — with the purpose of evaluating diabetes management and control (source). Skipping this step can jeopardize coverage approval.
On the beneficiary’s side, proper training on the device is a firm prerequisite. A person receiving a CGM — or their caregiver — must demonstrate sufficient training to operate the monitor correctly before Medicare coverage is granted (source). This requirement reflects Medicare’s focus on ensuring that covered equipment is used effectively and safely.
Suppliers also carry documentation obligations. Under CMS policy rules, a Written Order Prior to Delivery is required for CGM devices, and claims submitted without meeting this standard may be denied as not reasonable and necessary (source). Beneficiaries who work with participating DME suppliers that accept Medicare assignment can expect to pay only the coinsurance and deductible — no additional charges beyond the Medicare-approved amount (source).
How Supplies Are Handled Under Medicare’s CGM Benefit
One practical aspect of CGM coverage that often causes confusion is how supplies are billed. Medicare’s policy groups all components necessary for CGM operation — including sensors and transmitters — into a single supply allowance. Any attempt by a supplier to bill these items separately is treated as unbundling and will be denied (source). Understanding this bundling rule helps beneficiaries recognize what their supplier should and should not be billing.
It is also helpful to know that CGMs must be prescribed in line with their FDA-approved indications for use. The prescription must align with the device’s intended purpose as recognized by the FDA — an additional layer of compliance that providers and suppliers must satisfy for claims to be processed correctly (source).
Why You Should Learn More About Medicare Glucose Monitor Coverage Today
Medicare’s coverage for continuous glucose monitors has expanded notably in recent years, making these devices accessible to a larger population of people managing diabetes — from long-term insulin users to individuals experiencing dangerous blood sugar lows without insulin therapy. Navigating the eligibility criteria, provider requirements, and supplier rules may seem complex, but each step serves a clear purpose: ensuring that qualifying beneficiaries receive the tools their health depends on. For anyone living with diabetes and enrolled in Medicare, understanding the scope of this benefit, the conditions that must be met, and the protections that come with working through approved suppliers represents a genuinely worthwhile area of health literacy.